Reactive astrocytes as potential manipulation targets in novel cell replacement therapy of Parkinson's disease.
Parkinson' disease (PD) is a most common and debilitating degenerative disease resulted from massive loss of dopamine neurons in the substantia nigra pars compacta, which is characterized by severe motor symptoms of tremor, bradykinesia, rigidity and postural instability. Protection of nigral dopamine neurons from progressive degenerative death and cell replacement of novel dopamine neurons are hopeful strategies against PD in humans. The reactive astrocytes or functional activation of astrocytes abundantly occurred in brain insults including trauma, ischemia, and 6-OHDA or MPTP-treated PD animal models. Although they were traditionally assumed to impede neuronal regeneration by forming glial scars, growing evidence has indicated that reactive astrocytes do offer crucial benefits in functional recovery of brain injuries. The reactive astrocytes can produce various neurotrophic factors for neuron survival, synthesize extracellular substrates for axonal outgrowth and synaptogenesis, act as scavengers for free radical and excess glutamate, and promote neurogenesis of neural progenitor cells in the adult brains. We thereafter hypothesize that reactive astrocytes may also play important roles in the protection of nigral dopamine neurons or transplanted dopamine cells through their neurotrophic functions and active interaction with dopamine neurons or neural progenitor cells. Future approaches deserve to target on neurotrophic functions of reactive astrocytes in the basal ganglia and interventions to facilitate survival and axonal regeneration of dopamine neurons or differentiation of dopamine progenitor cells. Novel pharmaceutical and cell replacement strategies will hopefully be developed by potential manipulation of reactive astrocytes in the basal ganglia in prevention and treatment of Parkinson's disease.
Chen
Liang-Wei
LW
Institute of Neurosciences, The Fourth Military Medical University, Xi'an 710032, PR China. lwchen@pub.xaonline.com
Yung
Kin-Lam
KL
Chan
Ying-Shing
YS
D000818:Animals; D000975:Antioxidants / Q000378:metabolism; D001253:Astrocytes / Q000378:metabolism / Q000473:pathology / Q000502:physiology; D064987:Cell- and Tissue-Based Therapy; D016207:Cytokines / Q000096:biosynthesis; D018846:Excitatory Amino Acids / Q000502:physiology; D018698:Glutamic Acid / Q000502:physiology; D006801:Humans; D009414:Nerve Growth Factors / Q000096:biosynthesis; D010300:Parkinson Disease / Q000473:pathology / Q000628:therapy*
D000975:Antioxidants; D016207:Cytokines; D018846:Excitatory Amino Acids; D009414:Nerve Growth Factors; D018698:Glutamic Acid